Screener
Amphastar Pharmaceuticals AMPH Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $223.61M+19.1% | $170.94M-6.5% | $170.18M+12.2% | $216.27M+12.6% | $187.69M-1.0% | ||
| $66.51M+50.9% | $121.01M+124% | $112.64M+60.8% | $59.94M+2.7% | $44.06M+56.5% | ||
| $144.86M+8.9% | $147.85M+2.2% | $143.56M+5.3% | $146.81M+5.1% | $132.98M+1.2% | ||
| $179.91M-6.2% | $170.19M-8.2% | $176.89M+15.1% | $185.93M+42.7% | $191.73M+56.6% | ||
| $630.95M+8.6% | $633.68M+7.8% | $636.02M+19.1% | $639.47M+17.1% | $580.83M+20.3% | ||
| $316.06M+1.9% | $307.23M-0.1% | $310.57M+4.4% | $308.69M+4.5% | $310.24M+7.7% | ||
| $647.83M+12.0% | $559.62M-4.3% | $565.97M-4.2% | $572.24M-3.8% | $578.5M-3.7% | ||
| $1.74B+8.0% | $1.65B+1.3% | $1.63B+3.3% | $1.67B+7.8% | $1.62B+8.3% | ||
| $251.37M+50.9% | $152.69M-13.2% | $148.35M-5.5% | $190.84M+24.5% | $166.55M+26.9% | ||
| $2.49M+168% | $1.67M+646% | $1.64M+601% | $923K+266% | $927K+272% | ||
| $263.21M+49.2% | $164.48M-17.4% | $158.16M-9.0% | $205.23M+29.1% | $176.41M+28.8% | ||
| $609.56M+0.3% | $609.8M+1.0% | $608.75M+1.2% | $608.58M+2.0% | $607.73M+3.6% | ||
| $975.61M+13.7% | $874.77M0.0% | $840.49M-0.6% | $889.48M+8.8% | $857.85M+10.2% | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| $703.65M+12.6% | $673.3M+13.3% | $666.88M+17.2% | $642.45M+21.0% | $625.1M+27.5% | ||
| $1.74B+8.0% | $1.65B+1.3% | $1.63B+3.3% | $1.67B+7.8% | $1.62B+8.3% |
FAQ
- What are Amphastar Pharmaceuticals's total assets?
- Amphastar Pharmaceuticals (AMPH) holds $1.7B in total assets, up 8.0% year over year.
- How much cash does Amphastar Pharmaceuticals have?
- Amphastar Pharmaceuticals holds $223.6M in cash and equivalents.
- Can Amphastar Pharmaceuticals cover its short-term obligations?
- Its current ratio is 2.40 — current assets exceed current liabilities.
- Where does Amphastar Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
